APO RESEARCH · REPORT
PD-L1 and PIK3CA Testing
PD-L1 Biomarker Testing measures the amount of PDL1 on cancer cells. PDL1 is a protein that helps keep immune cells from attacking nonharmful cells in the body. Normally, the immune system fights foreign substances like viruses and bacteria, and not your own healthy cells. Some cancer cells have high amounts of PDL1. This allows the cancer cells to "trick" the immune system, and avoid being attacked as foreign, harmful substances.
Product & engineering
Understand the product.
PD-L1 Biomarker Testing measures the amount of PDL1 on cancer cells. PDL1 is a protein that helps keep immune cells from attacking nonharmful cells in the body. Normally, the immune system fights foreign substances like viruses and bacteria, and not your own healthy cells. Some cancer cells have high amounts of PDL1. This allows the cancer cells to "trick" the immune system, and avoid being attacked as foreign, harmful substances.
Current PD-L1 testing is based on immunohistochemistry (IHC) methods. Immunohistochemistry (IHC) is the process whereby antibodies are used to detect proteins (antigens) in cells within a tissue section (for instance liver, pancreas or the heart).
PD-L1 is a ligand that binds to PD-1 (programmed cell death-1), expressed on activated T cells, to evade anti-tumor responses. PD-L1 plays a role in inhibiting T cell activation and proliferation and has emerged as an important target in cancer treatment. PD-L1 protein detection by immunohistochemistry (IHC) testing is widely used as a predictive biomarker assay for anti–PD-1/PD-L1 therapies.
PIK3CA is a gene that encodes a lipid kinase involved in multiple signaling pathways. These pathways influence cellular functions such as growth, death, and proliferation. PIK3CA mutations activate the PI3K-PTEN-AKT pathway, which is downstream from both the EGFR and the RAS-RAF-MAPK pathways. PIK3CA mutations may cause oncogenic transformation independent of RAS or RAF mutations.
PIK3CA mutations occur in about 15% to 30% of breast, endometrial, and colon cancers. They occur less frequently in lung cancer and other types of cancer. Presence of PIK3CA mutations is associated with poor prognosis and lack of response to specific therapies in patients with breast, endometrial, or colon cancer.
Selected research
Industry Research
PD-L1 and PIK3CA Testing Industry Research Report 2026
Market perspective
PD-L1 Biomarker Testing measures the amount of PDL1 on cancer cells. PDL1 is a protein that helps keep immune cells from attacking nonharmful cells in the body. Normally, the immune system fights foreign substances like viruses and bacteria, and not your own healthy cells. Some cancer cells have high amounts of PDL1. This allows the cancer cells to "trick" the immune system, and avoid being attacked as foreign, harmful substances.
Current PD-L1 testing is based on immunohistochemistry (IHC) methods. Immunohistochemistry (IHC) is the process whereby antibodies are used to detect proteins (antigens) in cells within a tissue section (for instance liver, pancreas or the heart).
PD-L1 is a ligand that binds to PD-1 (programmed cell death-1), expressed on activated T cells, to evade anti-tumor responses. PD-L1 plays a role in inhibiting T cell activation and proliferation and has emerged as an important target in cancer treatment. PD-L1 protein detection by immunohistochemistry (IHC) testing is widely used as a predictive biomarker assay for anti–PD-1/PD-L1 therapies.
Read the full market overview
PIK3CA is a gene that encodes a lipid kinase involved in multiple signaling pathways. These pathways influence cellular functions such as growth, death, and proliferation. PIK3CA mutations activate the PI3K-PTEN-AKT pathway, which is downstream from both the EGFR and the RAS-RAF-MAPK pathways. PIK3CA mutations may cause oncogenic transformation independent of RAS or RAF mutations.
PIK3CA mutations occur in about 15% to 30% of breast, endometrial, and colon cancers. They occur less frequently in lung cancer and other types of cancer. Presence of PIK3CA mutations is associated with poor prognosis and lack of response to specific therapies in patients with breast, endometrial, or colon cancer.
The classification of PD-L1 and PIK3CA Testing Product includes PD-L1 Testing and PIK3CA Testing. PD-L1 accounted for a share of 80% in the global PD-L1 and PIK3CA Testing Product market.
PD-L1 and PIK3CA Testing Product is widely used in Hospital, Diagnostic Center and Other. In PD-L1 and PIK3CA Testing Product market, the Diagnostic Center holds an important share in terms of Application.
North America is the largest consumption place, with a market share nearly 57% . Following North America, Europe is the second largest consumption place with the market share of 28%.
Market competition is intense. Agilent Technologies, Roche, QIAGEN, Amoy Diagnostics, ACCB Biotech, etc. The top five vendors held 84% of the market share.
Report Scope
This report quantifies the global PD-L1 and PIK3CA Testing market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to PD-L1 and PIK3CA Testing.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
PD-L1 and PIK3CA Testing Market by Company
Agilent Technologies
Roche
QIAGEN
EntroGen
Amoy Diagnostics
ACCB Biotech
PD-L1 and PIK3CA Testing Segment by Type
PD-L1 Testing
PIK3CA Testing
PD-L1 and PIK3CA Testing Segment by Application
Hospital
Diagnostic Center
Others
PD-L1 and PIK3CA Testing Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global PD-L1 and PIK3CA Testing market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of PD-L1 and PIK3CA Testing and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of PD-L1 and PIK3CA Testing.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of PD-L1 and PIK3CA Testing companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- PD-L1 Testing
- PIK3CA Testing
Applications
- Hospital
- Diagnostic Center
- Others
Companies covered
- Agilent Technologies
- Roche
- QIAGEN
- EntroGen
- Amoy Diagnostics
- ACCB Biotech
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 PD-L1 and PIK3CA Testing by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 PD-L1 Testing
- 2.2.3 PIK3CA Testing
- 2.3 PD-L1 and PIK3CA Testing by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Hospital
- 2.3.3 Diagnostic Center
- 2.3.4 Others
- 2.4 Assumptions and Limitations
3 PD-L1 and PIK3CA Testing Breakdown Data by Type
- 3.1 Global PD-L1 and PIK3CA Testing Historic Market Size by Type (2021-2026)
- 3.2 Global PD-L1 and PIK3CA Testing Forecasted Market Size by Type (2027-2032)
4 PD-L1 and PIK3CA Testing Breakdown Data by Application
- 4.1 Global PD-L1 and PIK3CA Testing Historic Market Size by Application (2021-2026)
- 4.2 Global PD-L1 and PIK3CA Testing Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global PD-L1 and PIK3CA Testing Market Perspective (2021-2032)
- 5.2 Global PD-L1 and PIK3CA Testing Growth Trends by Region
- 5.2.1 Global PD-L1 and PIK3CA Testing Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 PD-L1 and PIK3CA Testing Historic Market Size by Region (2021-2026)
- 5.2.3 PD-L1 and PIK3CA Testing Forecasted Market Size by Region (2027-2032)
- 5.3 PD-L1 and PIK3CA Testing Market Dynamics
- 5.3.1 PD-L1 and PIK3CA Testing Industry Trends
- 5.3.2 PD-L1 and PIK3CA Testing Market Drivers
- 5.3.3 PD-L1 and PIK3CA Testing Market Challenges
- 5.3.4 PD-L1 and PIK3CA Testing Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top PD-L1 and PIK3CA Testing Players by Revenue
- 6.1.1 Global Top PD-L1 and PIK3CA Testing Players by Revenue (2021-2026)
- 6.1.2 Global PD-L1 and PIK3CA Testing Revenue Market Share by Players (2021-2026)
- 6.2 Global PD-L1 and PIK3CA Testing Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of PD-L1 and PIK3CA Testing Head Office and Area Served
- 6.4 Global PD-L1 and PIK3CA Testing Players, Product Type & Application
- 6.5 Global PD-L1 and PIK3CA Testing Manufacturers Established Date
- 6.6 Global PD-L1 and PIK3CA Testing Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America PD-L1 and PIK3CA Testing Market Size (2021-2032)
- 7.2 North America PD-L1 and PIK3CA Testing Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America PD-L1 and PIK3CA Testing Market Size by Country (2021-2026)
- 7.4 North America PD-L1 and PIK3CA Testing Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe PD-L1 and PIK3CA Testing Market Size (2021-2032)
- 8.2 Europe PD-L1 and PIK3CA Testing Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe PD-L1 and PIK3CA Testing Market Size by Country (2021-2026)
- 8.4 Europe PD-L1 and PIK3CA Testing Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific PD-L1 and PIK3CA Testing Market Size (2021-2032)
- 9.2 Asia-Pacific PD-L1 and PIK3CA Testing Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific PD-L1 and PIK3CA Testing Market Size by Country (2021-2026)
- 9.4 Asia-Pacific PD-L1 and PIK3CA Testing Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America PD-L1 and PIK3CA Testing Market Size (2021-2032)
- 10.2 South America PD-L1 and PIK3CA Testing Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America PD-L1 and PIK3CA Testing Market Size by Country (2021-2026)
- 10.4 South America PD-L1 and PIK3CA Testing Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa PD-L1 and PIK3CA Testing Market Size (2021-2032)
- 11.2 Middle East & Africa PD-L1 and PIK3CA Testing Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa PD-L1 and PIK3CA Testing Market Size by Country (2021-2026)
- 11.4 Middle East & Africa PD-L1 and PIK3CA Testing Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Agilent Technologies
- 12.1.1 Agilent Technologies Company Information
- 12.1.2 Agilent Technologies Business Overview
- 12.1.3 Agilent Technologies Revenue in PD-L1 and PIK3CA Testing Business (2021-2026)
- 12.1.4 Agilent Technologies PD-L1 and PIK3CA Testing Product Portfolio
- 12.1.5 Agilent Technologies Recent Developments
- 12.2 Roche
- 12.2.1 Roche Company Information
- 12.2.2 Roche Business Overview
- 12.2.3 Roche Revenue in PD-L1 and PIK3CA Testing Business (2021-2026)
- 12.2.4 Roche PD-L1 and PIK3CA Testing Product Portfolio
- 12.2.5 Roche Recent Developments
- 12.3 QIAGEN
- 12.3.1 QIAGEN Company Information
- 12.3.2 QIAGEN Business Overview
- 12.3.3 QIAGEN Revenue in PD-L1 and PIK3CA Testing Business (2021-2026)
- 12.3.4 QIAGEN PD-L1 and PIK3CA Testing Product Portfolio
- 12.3.5 QIAGEN Recent Developments
- 12.4 EntroGen
- 12.4.1 EntroGen Company Information
- 12.4.2 EntroGen Business Overview
- 12.4.3 EntroGen Revenue in PD-L1 and PIK3CA Testing Business (2021-2026)
- 12.4.4 EntroGen PD-L1 and PIK3CA Testing Product Portfolio
- 12.4.5 EntroGen Recent Developments
- 12.5 Amoy Diagnostics
- 12.5.1 Amoy Diagnostics Company Information
- 12.5.2 Amoy Diagnostics Business Overview
- 12.5.3 Amoy Diagnostics Revenue in PD-L1 and PIK3CA Testing Business (2021-2026)
- 12.5.4 Amoy Diagnostics PD-L1 and PIK3CA Testing Product Portfolio
- 12.5.5 Amoy Diagnostics Recent Developments
- 12.6 ACCB Biotech
- 12.6.1 ACCB Biotech Company Information
- 12.6.2 ACCB Biotech Business Overview
- 12.6.3 ACCB Biotech Revenue in PD-L1 and PIK3CA Testing Business (2021-2026)
- 12.6.4 ACCB Biotech PD-L1 and PIK3CA Testing Product Portfolio
- 12.6.5 ACCB Biotech Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst